Plasma autoantibodies against apolipoprotein B-100 peptide 210 in subclinical atherosclerosis.

Olga McLeod; Angela Silveira; Gunilla Nordin Fredrikson; Karl Gertow; Damiano Baldassarre; Fabrizio Veglia; Bengt Sennblad; Rona J Strawbridge; Malin Larsson; Karin Leander; Bruna Gigante; Jussi Kauhanen; Rainer Rauramaa; Andries J Smit; Elmo Mannarino; Philippe Giral; Steve E Humphries; Elena Tremoli; Ulf de Faire; John Ohrvik; Jan Nilsson; Anders Hamsten

doi:10.1016/j.atherosclerosis.2013.11.041

Plasma autoantibodies against apolipoprotein B-100 peptide 210 in subclinical atherosclerosis.

Olga McLeod, Angela Silveira, Gunilla Nordin Fredrikson, Karl Gertow, Damiano Baldassarre, Fabrizio Veglia, Bengt Sennblad, Rona J Strawbridge, Malin Larsson, Karin Leander, Bruna Gigante, Jussi Kauhanen, Rainer Rauramaa, Andries J Smit, Elmo Mannarino, Philippe Giral, Steve E Humphries, Elena Tremoli, Ulf de Faire, John OhrvikJan Nilsson, Anders Hamsten

Research output: Contribution to journal › Article › peer-review

Abstract

Experimental studies have suggested that autoimmunity is involved in atherosclerosis and provided evidence that both protective and pro-atherogenic immune responses exist. This concept has received support from small clinical studies implicating autoantibodies directed against apolipoprotein B-100 (apoB-100) in human atherosclerosis. We examined circulating autoantibodies directed against native and malondialdehyde (MDA)-modified epitope p210 of apoB-100 (IgG-p210nat and IgM-p210MDA) in relation to early atherosclerosis in a large, European longitudinal cohort study of healthy high-risk individuals.

Original language	English
Pages (from-to)	242-248
Journal	Atherosclerosis
Volume	232
Issue number	1
DOIs	https://doi.org/10.1016/j.atherosclerosis.2013.11.041
Publication status	Published - 2014

Subject classification (UKÄ)

Cardiology and Cardiovascular Disease

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.atherosclerosis.2013.11.041

http://www.ncbi.nlm.nih.gov/pubmed/24401246?dopt=Abstract

Cite this

McLeod, O., Silveira, A., Nordin Fredrikson, G., Gertow, K., Baldassarre, D., Veglia, F., Sennblad, B., Strawbridge, R. J., Larsson, M., Leander, K., Gigante, B., Kauhanen, J., Rauramaa, R., Smit, A. J., Mannarino, E., Giral, P., Humphries, S. E., Tremoli, E., de Faire, U., ... Hamsten, A. (2014). Plasma autoantibodies against apolipoprotein B-100 peptide 210 in subclinical atherosclerosis. Atherosclerosis, 232(1), 242-248. https://doi.org/10.1016/j.atherosclerosis.2013.11.041

@article{e742d3ffa870405ea2e5c41068513e6f,

title = "Plasma autoantibodies against apolipoprotein B-100 peptide 210 in subclinical atherosclerosis.",

abstract = "Experimental studies have suggested that autoimmunity is involved in atherosclerosis and provided evidence that both protective and pro-atherogenic immune responses exist. This concept has received support from small clinical studies implicating autoantibodies directed against apolipoprotein B-100 (apoB-100) in human atherosclerosis. We examined circulating autoantibodies directed against native and malondialdehyde (MDA)-modified epitope p210 of apoB-100 (IgG-p210nat and IgM-p210MDA) in relation to early atherosclerosis in a large, European longitudinal cohort study of healthy high-risk individuals.",

author = "Olga McLeod and Angela Silveira and {Nordin Fredrikson}, Gunilla and Karl Gertow and Damiano Baldassarre and Fabrizio Veglia and Bengt Sennblad and Strawbridge, {Rona J} and Malin Larsson and Karin Leander and Bruna Gigante and Jussi Kauhanen and Rainer Rauramaa and Smit, {Andries J} and Elmo Mannarino and Philippe Giral and Humphries, {Steve E} and Elena Tremoli and {de Faire}, Ulf and John Ohrvik and Jan Nilsson and Anders Hamsten",

year = "2014",

doi = "10.1016/j.atherosclerosis.2013.11.041",

language = "English",

volume = "232",

pages = "242--248",

journal = "Atherosclerosis",

issn = "1879-1484",

publisher = "Elsevier",

number = "1",

}

McLeod, O, Silveira, A, Nordin Fredrikson, G, Gertow, K, Baldassarre, D, Veglia, F, Sennblad, B, Strawbridge, RJ, Larsson, M, Leander, K, Gigante, B, Kauhanen, J, Rauramaa, R, Smit, AJ, Mannarino, E, Giral, P, Humphries, SE, Tremoli, E, de Faire, U, Ohrvik, J, Nilsson, J & Hamsten, A 2014, 'Plasma autoantibodies against apolipoprotein B-100 peptide 210 in subclinical atherosclerosis.', Atherosclerosis, vol. 232, no. 1, pp. 242-248. https://doi.org/10.1016/j.atherosclerosis.2013.11.041

TY - JOUR

T1 - Plasma autoantibodies against apolipoprotein B-100 peptide 210 in subclinical atherosclerosis.

AU - McLeod, Olga

AU - Silveira, Angela

AU - Nordin Fredrikson, Gunilla

AU - Gertow, Karl

AU - Baldassarre, Damiano

AU - Veglia, Fabrizio

AU - Sennblad, Bengt

AU - Strawbridge, Rona J

AU - Larsson, Malin

AU - Leander, Karin

AU - Gigante, Bruna

AU - Kauhanen, Jussi

AU - Rauramaa, Rainer

AU - Smit, Andries J

AU - Mannarino, Elmo

AU - Giral, Philippe

AU - Humphries, Steve E

AU - Tremoli, Elena

AU - de Faire, Ulf

AU - Ohrvik, John

AU - Nilsson, Jan

AU - Hamsten, Anders

PY - 2014

Y1 - 2014

N2 - Experimental studies have suggested that autoimmunity is involved in atherosclerosis and provided evidence that both protective and pro-atherogenic immune responses exist. This concept has received support from small clinical studies implicating autoantibodies directed against apolipoprotein B-100 (apoB-100) in human atherosclerosis. We examined circulating autoantibodies directed against native and malondialdehyde (MDA)-modified epitope p210 of apoB-100 (IgG-p210nat and IgM-p210MDA) in relation to early atherosclerosis in a large, European longitudinal cohort study of healthy high-risk individuals.

AB - Experimental studies have suggested that autoimmunity is involved in atherosclerosis and provided evidence that both protective and pro-atherogenic immune responses exist. This concept has received support from small clinical studies implicating autoantibodies directed against apolipoprotein B-100 (apoB-100) in human atherosclerosis. We examined circulating autoantibodies directed against native and malondialdehyde (MDA)-modified epitope p210 of apoB-100 (IgG-p210nat and IgM-p210MDA) in relation to early atherosclerosis in a large, European longitudinal cohort study of healthy high-risk individuals.

U2 - 10.1016/j.atherosclerosis.2013.11.041

DO - 10.1016/j.atherosclerosis.2013.11.041

M3 - Article

C2 - 24401246

SN - 1879-1484

VL - 232

SP - 242

EP - 248

JO - Atherosclerosis

JF - Atherosclerosis

IS - 1

ER -

Plasma autoantibodies against apolipoprotein B-100 peptide 210 in subclinical atherosclerosis.

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Cite this